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In rapid order, investigators (2, 3) reported that aureomycin was effective in most coccal infections and in some viral-like infections. It was shown that most organisms did not become resistant to this antibiotic, and that it was active against many organisms unaffected by streptomycin or penicillin (4). The action was said to be bacteriostatic rather than bactericidal (5).
CLINICAL STUDIES
The therapeutic effectiveness of topical applications of aureomycin ointment was studied in a variety of dermatoses. The investigations here reported cover a period of six months, from May to November of 1949. Of the salts of aureomycin used, the most suitable preparation was found to be aureomycin hydrochloride, made up in a base of lanolin, mineral oil and petrolatum, 30 milligrams to the gram. (3%). This ointment is stable and does not require refrigeration.
A total of 170 patients were treated with this preparation. The results are tabulated in the accompanying charts.
CUTANEOUS SENSITIVITY
In the group studied, 5 cases of mild contact dermatitis were observed; the dermatitis cleared within a week following cessation of therapy. A positive 48 hour patch test was elicited in two of these clinical reactors; the other three gave negative patch test results.
Seventy-four of the patients were subjected to the usual 48 hour patch testing two weeks, and again four weeks, after the initiation of therapy. A positive test was obtained in two of the seventy-four (both in the aforementioned cases of mild clinical dermatitis) and an equivocal reaction in two others.
SUMMARY AND CONCLUSIONS
A total of 170 patients, presenting a wide range of dermatoses were treated with aureomycin hydrochloride ointment (Lederle); 74 of these patients were patch tested two weeks, and again four weeks, after the initiation of therapy. Received for publication April 18, 1950.
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Our findings lead us to believe that aureomycin ointment (Lederle) is a potent therapeutic agent in the management of the superficial pyodermas. Stasis ulcers respond rapidly, but not completely, apparently by control of the secondary infection so frequently .present. Similarly, other dermatoses characterized by secondary bacterial infeetion are benefited by the ointment. Herpes simplex, verruca vulgaris, chronic hand eczemas and a miscellaneous group of dermatoses were, in the main, uninfluenced by the therapy.
